Altered Cell Modalities: Cancer Treatments and Nursing Management

Page 1: Altered Cell Modalities

  • Presenter: Dr. Vivek Agnihotri, DNP, APN, CCRN, Associate Professor

Page 2: Clinical Objectives

  • Differentiate cancer therapeutic modalities: surgery, radiation, chemotherapy, biologic therapies, and targeted agents.

  • Classify chemotherapeutic medications based on cell-cycle specificity and mechanism of action.

  • Distinguish delivery mechanisms and safety protocols between external beam teletherapy and internal brachytherapy.

  • Identify tissue toxicities, comprehensive nursing interventions, and nutritional support requirements for oncology patients.

Page 3: Goals of Cancer Therapy

  • Curative: Complete elimination and eradication of malignant disease.

  • Control: Slowing tumor progression, preventing cellular dissemination, and stabilizing disease burden.

  • Palliative: Relieving distressing symptoms, managing pain, and mitigating physical and psychosocial stress to promote comfort.

Page 4: Overview of Cancer Treatment Modalities

  • Surgical: Direct operative intervention to resect or debulk diseased tissue.

  • Radiation Therapy: Ionizing high-energy beams or isotope sources that damage targeted cellular DNA.

  • Chemotherapy: Pharmacologic agents that systemically destroy rapidly proliferating cells.

  • Biotherapy: Living organism-derived substances that alter biologic and immune responses against neoplastic cells.

  • Complementary & Alternative Medicine (CAM): Non-standard medical practices and products utilized alongside or outside conventional care.


Cancer treatment modalities

Pages 5–7: Surgical Oncology Applications

  • Clinical Indications:

    • Primary treatment modality of choice for localized solid tumors.

    • Surgical failure occurs predominantly due to occult or undetected metastasis present at the time of diagnosis.

  • Roles Across Treatment Continuum:

    • Diagnosis & Staging: Tissue biopsy and anatomic mapping of tumor extension.

    • Primary Treatment: Definitive curative surgical resection.

    • Preventive Care: Prophylactic removal of non-vital, high-risk premalignant tissues.

    • Palliative Care: Relief of mechanical obstruction, pain reduction, and symptom control.

    • Reconstructive / Rehabilitative: Functional and cosmetic restoration following radical tissue excision.

    • Supportive Care: Placement of vascular access devices (e.g., ports) or enteral feeding routes.

Page 8: Perioperative Nursing Management

  • Preoperative Priorities: Thorough patient and family education; clinical management of procedural anxiety.

  • Postoperative Priorities: Systematic pain management and targeted complication prevention:

    • Respiratory Complications: Atelectasis and Pneumonia.

    • Cardiovascular & Wound Complications: Deep vein thrombosis (DVT) and surgical site infections (SSI).

    • Psychosocial support for altered body image and recovery stress.

Pages 9–11: Radiation Therapy Principles & Teletherapy

  • Definition: Utilization of targeted ionizing radiation or radioisotopes to induce irreversible lethal DNA double-strand breaks in malignant cells.

  • Teletherapy (External Beam Therapy):

    • Radiation is delivered from an external ionizing source outside the patient.

    • Permanent tattoo markings guide daily stereotactic positioning.

    • The patient and their body excreta are never radioactive.

    • Specialized techniques include Cyber knife Rx.


External beam radiation therapy setup

Pages 12–13: Brachytherapy & Radiation Protection Protocols

  • Brachytherapy Delivery Modalities:

    • Sealed Brachytherapy: Radioactive seeds or needles are implanted within or directly adjacent to the tumor bed. The patient actively emits radiation, but body excreta are non-radioactive.

    • Unsealed Brachytherapy: Radioactive isotopes are administered orally, intravenously, or via intracavitary instillation. Both the patient and all body fluids/excreta are radioactive.


Prostate brachytherapy catheter and seed implant
  • Nursing and Radiation Safety Interventions:

    • Place patient in a private room with a dedicated private bathroom.

    • Healthcare workers must wear a personal Dosimeter badge at all times to monitor cumulative exposure.

    • Pregnant nursing personnel are strictly prohibited from caring for the patient.

    • Restrict patient visitors to a maximum duration of 12 hr\frac{1}{2}\,\text{hr} per visit and require them to maintain a minimum physical distance of 6 ft6\,\text{ft}.

    • Never handle dislodged radioactive implants with bare hands; use long-handled forceps to place items into a bedside lead container.

Pages 14–16: Radiation Complications & Skin Care Protocols

  • Site-Specific Adverse Effects:

    • Cutaneous desquamation and erythema.

    • Stomatitis and xerostomia (salivary gland dysfunction).

    • Localized alopecia, dysgeusia (altered taste), and profound fatigue.

    • Long-term tissue fibrosis, stricture, esophagitis, and hemorrhagic cystitis.


Radiation-induced oral mucositis progression
  • Patient Education for Irradiated Skin:

    • Wash the irradiated field gently using only tepid water and mild soap; pat dry rather than rubbing.

    • Use bare hands to clean the area instead of rough washcloths.

    • Avoid all unapproved powders, cosmetic lotions, ointments, and medicinal creams.

    • Protect irradiated tissue from direct heat sources and sunlight exposure.

    • Shave strictly with electric razors; wear loose, non-restrictive soft cotton garments.

    • Never scrub, rub off, or attempt to remove external skin tattoo markings.

Pages 17–22: Chemotherapy Administration, Dosing & Safe Handling

  • Mechanism: Destruction of rapidly dividing malignant cells by disrupting cellular DNA and interfering with cell division.

  • Routes of Administration: Oral, intravenous (IV), intra-arterial, intra-cavitary, and intra-thecal.


Chemotherapy extravasation tissue necrosis
  • Clinical Dosing Considerations:

    • Dosing calculations are strictly individualized according to the patient’s Total Body Surface Area (TBSA).

    • The medical oncologist sets treatment cycles and intervals based on cumulative organ toxicity and the predicted bone marrow recovery Nadir.

  • Occupational Safety Protocols:

    • Reconstitute and manipulate hazardous drugs inside a certified Class II biological safety cabinet.

    • Wear specialized protective gowns and chemotherapy-tested gloves during all handling, administration, and disposal steps.

    • Use Luer-Lock connectors exclusively on all IV tubing sets.

    • Dispose of all contaminated administration sets, supplies, and patient excreta as hazardous cytotoxic waste.

Pages 23–29: Chemotherapy Classifications & Adjuvant Agents

  • Alkylating Agents (Cell Cycle Non-Specific):

    • Examples: Cyclophosphamide (Cytoxan), Cisplatin (Platinol), Busulfan (Myleran), Chlorambucil (Leukeran), Mechloretamine (nitrogen mustard).

    • Mechanism: Cross-links DNA strands to halt replication and transcription.

    • Key Toxicities: Myelosuppression (anemia, neutropenia, thrombocytopenia), nephrotoxicity, neurotoxicity, and hemorrhagic cystitis.

  • Antimetabolites (Cell Cycle Specific – S Phase):

    • Examples: Methotrexate, 5FU (5-fluorouracil), 6MP (6-mercaptopurine), Cytarbine (Cytosine arabinoside, ARA-C).

    • Mechanism: Mimics essential metabolic building blocks to inhibit DNA and RNA synthesis.

    • Key Toxicities: Severe bone marrow suppression, gastrointestinal distress, alopecia, rash, hepatic inflammation, and fatigue.

  • Anti-Tumor Antibiotics (Cell Cycle Non-Specific):

    • Examples: Doxorubicin (Adriamycin), Bleomycin (Blenoxane), Plicamycin (Mithramycin), Mitomycin (Mutamycin).

    • Mechanism: Intercalates within DNA base pairs, fracturing the helical strand.

    • Key Toxicities: Cardiotoxicity, pulmonary toxicity, hepatotoxicity, and myelosuppression.

  • Antimitotics (Cell Cycle Specific – M Phase):

    • Examples: Vincristine (Oncovin), Vinblastine (Velban), Paclitaxel (Taxol).

    • Mechanism: Disrupts mitotic spindle formation to inhibit cell division.

    • Key Toxicities: Severe vesicant potential, hypersensitivity reactions, and chemotherapy-induced peripheral neuropathy (CIPN).

  • Hormonal Agents:

    • Examples: Tamoxifen (Nolvadex), Evista (Raloxifene), Corticosteroids (Prednisone), Leuprolied (Lupron), Golserelin (Zoladex), Femara (Letrozole), Arimidex (Anastrozole), and specific sex steroids (androgens, estrogens, progesterone).

  • Topoisomerase Inhibitors (Cell Cycle Specific – S Phase):

    • Examples: Irinotecan, Topotecan.

    • Mechanism: Inhibits topoisomerase I enzymes responsible for relieving torsional tension, winding, and supercoiling during DNA replication.

  • Adjuvant & Supportive Pharmacotherapy:

    • Antiemetics: Zofran (ondansetron), Kytril (Granisetron), Anzemet (dolasetron).

    • Bone Protection: Pamindronate (Aredia).

    • Bladder Cytoprotection (against ifosfamide/cyclophosphamide urotoxicity): Mesna (mesnex).

    • Radioprotection / Chemoprotection: Amifostine (ethyol).

    • Cardioprotection (against anthracyclines): Doxruzoxane (zinecard).

Pages 30–32: General Toxicities & Standard Nursing Protocols

  • Major Systemic Toxicities:

    • Bone marrow suppression (pancytopenia), GI mucosal injury, alopecia, secondary carcinogenesis, reproductive gonadal toxicity, chemo-brain (cognitive dysfunction), and hyperuricemia secondary to rapid tumor lysis.

  • Standard Nursing Protocols for Administration:

    • Obtain detailed medical history, baseline allergy profile, height, weight, and signed informed consent.

    • Review baseline laboratory diagnostics (CBC, hepatic and renal panels).

    • Perform mandatory independent dual-verification of orders and drug calculations with a second chemotherapy-certified registered nurse.

    • Confirm blood return and verify intravenous patency before, during, and after vesicant infusion.

Pages 33–36: Nursing Care for Common Oncology Complications

  • Stomatitis / Mucositis:

    • Inspect oral mucosa and dentition on a daily schedule.

    • Cleanse with an ultra-soft toothbrush; do not floss.

    • Avoid alcohol-based commercial mouthwashes; utilize topical mucosal analgesics as prescribed.

    • Apply water-based lip and oral lubricants; eliminate tobacco, ethanol, hard candy, and thermal/spicy dietary irritants.

  • Absolute Neutropenia:

    • Place in a private room; assign healthcare workers to evaluate this patient first.

    • Perform rigorous hand hygiene using alcohol-based rubs before and after patient contact.

    • Enforce strict aseptic technique for all invasive vascular or catheter interventions.

    • Monitor daily CBC with differential; monitor vital signs including temperature.

    • Notify the healthcare provider immediately for any temperature elevation: Temperature>100.4∘F\text{Temperature} > 100.4^\circ\text{F}.

    • Institute a low-bacteria diet (exclude all fresh, unwashed fruits, raw vegetables, and rare/partially cooked meats).

    • Prohibit standing water or bedside humidifiers; administer Filgrastim (Neupogen) as ordered.

  • Thrombocytopenia (Bleeding Risk):

    • Use soft toothbrushes and electric razors exclusively; handle and reposition gently.

    • Avoid invasive trauma: prohibit rectal temperatures, suppositories, and unnecessary IM/IV punctures.

    • Defer elective dental procedures while counts are depressed; monitor platelet values and inspect the skin for petechiae and ecchymosis.

  • Chemotherapy-Induced Peripheral Neuropathy (CIPN):

    • Wear closed-toed shoes with thick protective soles; complete daily visual foot inspections for lesions.

    • Protect extremities against thermal injury in cold weather; wear protective gloves when washing dishes or gardening.

    • Change postural positions slowly; eliminate loose throw rugs, clutter, and obstacles; utilize stair handrails.

Pages 37–42: Biotherapy, Targeted Therapies & Vaccines

  • Cytokines:

    • Interferons (Interferon alfa 2a, Interferon alfa 2b): Augment innate immune surveillance and cell-mediated toxicity.

    • Interleukins (Interleukin 2): Promote T-cell proliferation and immune activation.

  • Colony Stimulating Factors (Hematopoietic Growth Factors):

    • Erythropoietin (Epogen, Procrit): Stimulates erythrocyte (RBC) synthesis.

    • Filgrastim (Neupogen), Pegfilgrastim (Neulesta), Sargramostin (Granulocyte): Increase leukocyte and granulocyte counts (monitor patients for bone pain).

  • Tyrosine Kinase Inhibitors: Imatinib (Gleevec), Erlotinib (Tarceva), Crizotinib (Xalkori).

  • Monoclonal Antibodies (MAB):

    • Trastuzumab (Herceptin): Targets HER2 receptor overexpression in specific breast cancers.

    • Rituximab (Rituxan): Targets CD20 in non-Hodgkin's Lymphoma (NHL).

    • Cetuximab (Erbitux): Targets EGFR in metastatic colorectal cancer (CRC).

    • Bevacizumab (Avastin): Anti-VEGF antibody that inhibits tumor angiogenesis in metastatic CRC.

  • Cancer Vaccines:

    • Utilized primarily for active therapy rather than prophylactic disease prevention.

    • FDA-Approved Agents: Sipuleucel-T (Provenge®) for refractory prostate cancer; BCG intravesical vaccine for superficial bladder cancer; Oncovax for colorectal malignancies.


Classification of cancer vaccines

Pages 43–44: Complementary and Alternative Medicine (CAM)

  • Epidemiology: Over $34 billion\$34\text{ billion} is spent annually by Americans on CAM, with 50%50\% of cancer patients incorporating non-traditional practices.

  • Clinical Considerations:

    • Patients must be cautioned against delaying, discontinuing, or substituting unproven therapies in place of standard curative regimens.

    • Exercise extreme caution regarding unrealistic curative guarantees or unscientific claims.

    • Natural substances must not be assumed safe or physiologically inert, as herbals and supplements frequently interact with conventional chemotherapeutic agents.